Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 3: Pharmacoeconomics in Oncology: Direct and Indirect Costs
Submit an article Journal homepage
466
Views
5
CrossRef citations to date
0
Altmetric
Original research

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

Terence Khooa Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6765-7889View further author information
ORCID Icon &
Lan Gaob Deakin Health Economics, Centre for Population Health Research, Faculty of Health, Deakin University, Burwood, AustraliaORCID Iconhttps://orcid.org/0000-0001-9734-1140View further author information
ORCID Icon
Pages 415-423 | Received 09 Sep 2020, Accepted 04 Nov 2020, Published online: 06 Dec 2020

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now

Articles from other publishers (4)

Mousa Alali & Maher Saifo. (2023) Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review. Journal of Immunotherapy and Precision Oncology 6:3, pages 140-149.
Crossref
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, Hamdy M. Abdel-Rahman & Mohamed Abdel-Aziz. (2023) Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review. RSC Advances 13:27, pages 18825-18853.
Crossref
Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu & Qilin Zhang. (2022) Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China. Frontiers in Pharmacology 13.
Crossref
Haijing Guan, Chunping Wang, Chen Chen, Sheng Han & Zhigang Zhao. (2022) Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China. Frontiers in Oncology 12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.